成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Tavaborole
174671-46-6

Tavaborole synthesis

7synthesis methods
Tavaborole, also known as AN-2690 (trade name Kerydin) is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014. Tavaborole inhibits an essential fungal enzyme, Leucyl-tRNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects were observed in any of its clinical trials.
Synthetic Routes
  • ROUTE 1
  • 202112077180598496.jpg

    Baker, Stephen J.; Zhang, Yong-Kang; Akama, Tsutomu; Lau, Agnes; Zhou, Huchen; Hernandez, Vincent; Mao, Weimin; Alley, M. R. K.; Sanders, Virginia; Plattner, Jacob J. Discovery of a New Boron-?Containing Antifungal Agent, 5-?Fluoro-?1,?3-?dihydro-?1-?hydroxy-?2,?1-?benzoxaborole (AN2690)?, for the Potential Treatment of Onychomycosis. Journal of Medicinal Chemistry. Volume 49. Issue 15. Pages 4447-4450. Journal. (2006).

  • ROUTE 2
  • 202112074500199804.jpg

    : Li, Xun; Pang, Guoxin; Song, Fangru; Huang, Shuqing. Preparation method of easily purified benzoxaborolane antifungal drug. Assignee?Anhui Xianhe Pharmaceutical Research Co., Ltd., Peop. Rep. China. CN?108358961. (2018).

  • ROUTE 3
  • 202112073028371858.jpg

    Baker, Stephen J.; Akama, Tsutomu; Alley, Michael Richard Kevin; Benkovic, Stephen J.; Dipierro, Michael; Hernandez, Vincent S.; Hold, Karin M.; Kennedy, Isaac; Likhotvorik, Igor; Mao, Weimin; Maples, Kirk R.; Plattner, Jacob J.; Rock, Fernando; Sanders, Virginia; Stemphoski, Aaron M.; Yiannikouros, George Petros; Zegar, Siead; Zhang, Yong-Kang; Zhou, Huchen. Preparation of boron-containing small molecules and nucleosides for treating fungal infections. Assignee?Anacor Pharmaceuticals, Inc., USA. WO?2007078340. (2007).

  • ROUTE 4
  • 202112072556147020.jpg

    Baker, Stephen J.; Akama, Tsutomu; Alley, Michael Richard Kevin; Benkovic, Stephen J.; Dipierro, Michael; Hernandez, Vincent S.; Hold, Karin M.; Kennedy, Isaac; Likhotvorik, Igor; Mao, Weimin; Maples, Kirk R.; Plattner, Jacob J.; Rock, Fernando; Sanders, Virginia; Stemphoski, Aaron M.; Yiannikouros, George Petros; Zegar, Siead; Zhang, Yong-Kang; Zhou, Huchen. Preparation of boron-containing small molecules and nucleosides for treating fungal infections. Assignee?Anacor Pharmaceuticals, Inc., USA. WO?2007078340. (2007).

  • ROUTE 5
  • 202112079692534794.jpg

    Merchant, Rupa Sudhir; Merchant, Aditya Sudhir; Limbad, Piyushkumar Bhikhalal; Pansuriya, Akshay Madhubhai. A novel and improved process for the preparation of tavaborole and its intermediates. Assignee?Halcyon Labs Private Limited, India. IN?201721039067. (2019).

202112077180598496.jpg

Baker, Stephen J.; Zhang, Yong-Kang; Akama, Tsutomu; Lau, Agnes; Zhou, Huchen; Hernandez, Vincent; Mao, Weimin; Alley, M. R. K.; Sanders, Virginia; Plattner, Jacob J. Discovery of a New Boron-?Containing Antifungal Agent, 5-?Fluoro-?1,?3-?dihydro-?1-?hydroxy-?2,?1-?benzoxaborole (AN2690)?, for the Potential Treatment of Onychomycosis. Journal of Medicinal Chemistry. Volume 49. Issue 15. Pages 4447-4450. Journal. (2006).

-

Yield:174671-46-6 81%

Reaction Conditions:

with sulfuric acid at 20; for 4 h;

Steps:

10
A mixture of crude (4-fluoro-2-(hydroxymethyl) phenyl)boronic acid (3 g) and 10% H2S04 solution (20 mL) is stirred at room temperature for 4 hrs. Water is added, and the mixture is extracted with ethyl acetate. The organic layer is washed with brine and dried on anhydrous sodium sulfate. The solvent is removed under reduced pressure, and the residue is treated with MTBE to afford benzo[c] [l,2]oxaborole-l,5(3H)-diol (Yield: 81%; Purity: 95%).

References:

BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.;PULLAGURLA, Manik Reddy;NANDA KUMAR, Mecheril Valsan;PITTA, Bhaskar Reddy;RANGISETTY, Jagadeesh Babu WO2017/183043, 2017, A1 Location in patent:Page/Page column 34

Tavaborole Related Search: